Last reviewed · How we verify
dorzolamide/timolol
dorzolamide/timolol is a Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination Small molecule drug developed by CT Glaucoma Associates. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension. Also known as: latanoprost, timolol/brimonidine/dorzolamide/bimatoprost, Cosopt, Glaucotensil TD.
Dorzolamide inhibits carbonic anhydrase to reduce aqueous humor production, while timolol blocks beta-adrenergic receptors to further decrease intraocular pressure.
Dorzolamide/timolol is a medication used to treat high pressure inside the eye, including glaucoma, and is typically used when a beta blocker alone is insufficient. It is a combination of dorzolamide hydrochloride and timolol maleate, a beta-1 adrenergic receptor antagonist.
At a glance
| Generic name | dorzolamide/timolol |
|---|---|
| Also known as | latanoprost, timolol/brimonidine/dorzolamide/bimatoprost, Cosopt, Glaucotensil TD |
| Sponsor | CT Glaucoma Associates |
| Drug class | Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination |
| Target | Carbonic anhydrase II / Beta-adrenergic receptors (β1 and β2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Dorzolamide is a topical carbonic anhydrase inhibitor that decreases aqueous humor secretion in the eye by inhibiting the enzyme carbonic anhydrase II. Timolol is a non-selective beta-adrenergic antagonist that reduces aqueous humor production and may increase uveoscleral outflow. Together, these complementary mechanisms provide additive intraocular pressure reduction.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular irritation or discomfort
- Blurred vision
- Bitter taste
- Allergic conjunctivitis
- Systemic beta-blocker effects (bradycardia, fatigue)
Key clinical trials
- Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) (PHASE3)
- Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety (PHASE4)
- How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure? (PHASE4)
- Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dorzolamide/timolol CI brief — competitive landscape report
- dorzolamide/timolol updates RSS · CI watch RSS
- CT Glaucoma Associates portfolio CI
Frequently asked questions about dorzolamide/timolol
What is dorzolamide/timolol?
How does dorzolamide/timolol work?
What is dorzolamide/timolol used for?
Who makes dorzolamide/timolol?
Is dorzolamide/timolol also known as anything else?
What drug class is dorzolamide/timolol in?
What development phase is dorzolamide/timolol in?
What are the side effects of dorzolamide/timolol?
What does dorzolamide/timolol target?
Related
- Drug class: All Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination drugs
- Target: All drugs targeting Carbonic anhydrase II / Beta-adrenergic receptors (β1 and β2)
- Manufacturer: CT Glaucoma Associates — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Open-angle glaucoma
- Indication: Drugs for Ocular hypertension
- Also known as: latanoprost, timolol/brimonidine/dorzolamide/bimatoprost, Cosopt, Glaucotensil TD
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing